Magni A, Pradal U, Cazzola G, Mastella G
Centro Fibrosi Cistica, Verona, Italia.
Pediatr Med Chir. 1990 Sep-Oct;12(5):531-4.
20 CF patients, aged from 16.5 to 31.7 years, with chronic pulmonary infection due to Pseudomonas, were included in an open trial to study the efficacy of ciprofloxacin on respiratory exacerbation. Ciprofloxacin was given orally at the dose of 1500 mg/die for ten days. 16 patients concluded the entire treatment with clear clinical improvement, based on a score including 11 parameters. There has also been a significant improvement in the pulmonary function tests, and a tendency of Rx score to decrease. 4 patients interrupted the treatment on the fifth day because of clinical inefficacy. There was no increase of Pseudomonas resistance to ciprofloxacin at the end of the treatment; 30 days after no strain of pseudomonas was found resistant. We observed side-effects in 5 patients, but in no case it was necessary to discontinue the treatment. Ciprofloxacin may be considered as a good alternative to the more established antibiotic strategy in the treatment of Pseudomonas lung exacerbations in CF.
20名年龄在16.5至31.7岁之间、因铜绿假单胞菌引起慢性肺部感染的囊性纤维化（CF）患者被纳入一项开放试验，以研究环丙沙星对呼吸道加重的疗效。环丙沙星以每日1500毫克的剂量口服，持续十天。16名患者基于包含11项参数的评分，临床症状明显改善，完成了整个治疗。肺功能测试也有显著改善，X线评分有下降趋势。4名患者因临床治疗无效在第五天中断治疗。治疗结束时铜绿假单胞菌对环丙沙星的耐药性没有增加；30天后未发现有对环丙沙星耐药的铜绿假单胞菌菌株。我们在5名患者中观察到了副作用，但在任何情况下都无需停药。在治疗CF患者的铜绿假单胞菌肺部加重时，环丙沙星可被视为比更常用的抗生素策略更好的替代药物。
